Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Telik, Inc. (NasdaqNM:TELK)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Financials
Recent Events
Aug  6Earnings Announcement
Location
750 Gateway Boulevard
South San Francisco, CA 94080
Phone: (650) 244-9303
Fax: (650) 244-9388
Email: inquiry@telik.com
Employees (last reported count): 43
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 47%
·Over the last 6 months:
 · one insider buy; 25.0K shares (0.2% of insider shares)
·Institutional: 37% (71% of float)
(43 institutions)
·Net Inst. Buying: 2.27M shares (+20.82%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Telik, Inc. is a biopharmaceutical company working to discover, develop and commercialize drugs for which there is significant demand for new therapies. The Company's most advanced product development programs are for the treatment of cancer and diabetes. Telik's efforts are concentrated on four major diseases: cancer, diabetes, inflammatory diseases and stroke. The Company's two most advanced product candidates are for cancer treatment. TLK286, which entered clinical trials in January 2000, is being developed for the treatment of chemotherapy-resistant cancers. TLK199, a small molecule that accelerates recovery from chemotherapy-induced depletion of white blood cells, or neutropenia, offers a potential alternative for the treatment of blood disorders associated with this condition. In addition, the Company has discovered novel insulin receptor activators for the treatment of Type 2 diabetes.
More from Market Guide: Expanded Business Description

Financial Summary
Telik, Inc. is a biopharmaceutical company working to discover, develop, and commercialize small molecule drugs to treat serious diseases for which there is significant demand for new therapies. For the six months ended 6/30/01, revenues fell 33% to $894 thousand. Net loss applicable to Common fell 38% to $7.9 million. Revenues reflect the recognition of deferred contract revenues over a longer period. Lower loss reflects the absence of $4.7 million in preferred stock dividends.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Michael Wick, M.D., Ph.D., 55
Chairman, Pres, CEO
$450K--  
Cynthia Butitta, 46
CFO, Chief Operating Officer
125K$38K
Jacqueline Dombroski, Ph.D.
VP, Regulatory Affairs and Quality Assurance
--  --  
Reinaldo Gomez, Ph.D., 55
VP-Product Devel.
185K--  
Graeme Martin, Ph.D.
CTO
--  --  
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:TELKAs of 31-Aug-2001
Price and Volume
52-Week Low
on 13-Mar-2001
$3.625
Recent Price$10.05 
52-Week High
on 5-Sep-2000
$14.563
Daily Volume (3-month avg)141.0K
Daily Volume (10-day avg)32.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y]
52-Week Change-26.6%
52-Week Change
relative to S&P500
-1.5%
Share-Related Items
Market Capitalization$231.8M
Shares Outstanding23.1M
Float12.2M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$1.47 
Earnings (ttm)-$0.61 
Earnings (mrq)-$0.19 
Sales (ttm)$0.12 
Cash (mrq)$1.37 
Valuation Ratios
Price/Book (mrq)6.83 
Price/EarningsN/A 
Price/Sales (ttm)86.56 
Income Statements
Sales (ttm)$2.36M
EBITDA (ttm)-$13.4M
Income available to common (ttm)-$12.3M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-34.25%
Return on Equity (ttm)-37.82%
Financial Strength
Current Ratio (mrq)8.32 
Debt/Equity (mrq)0 
Total Cash (mrq)$31.4M
Short Interest
As of 8-Aug-2001
Shares Short115.0K
Percent of Float0.9%
Shares Short
(Prior Month)
160.0K
Short Ratio0.85 
Daily Volume136.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Event data provided by CCBN. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.